Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 7, 2006, Pages 662-666

  Zwitter, Matjaz ^a   Kovac, Viljem ^a   Smrdel, Uros ^a   Strojan, Primoz ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cisplatin; Gemcitabine; Hyperfractionation; Non small cell lung cancer; Radiotherapy; Sensitization

Indexed keywords

CISPLATIN; CORTICOSTEROID; GEMCITABINE; RADIOSENSITIZING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE FREE SURVIVAL; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOPOIESIS; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LUNG VOLUME; MALAISE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROIMAGING; NEUTROPENIA; PARAPLEGIA; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SKULL IRRADIATION; SURVIVAL RATE; THROMBOCYTOPENIA; WEIGHT REDUCTION; CLINICAL TRIAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION INJURY;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE;

EID: 34247866512     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200609000-00010     Document Type: Article

References (31)

1. Rinaldi M, Crino L. Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer. Lung Cancer 2001;34(suppl 4):S25-S30.
2. Santo A, Pedersini R, Pasini F, et al. A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis. Lung Cancer 2001;34(suppl 4):S15-S20.
3. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
4. Rowell N, O'Rourke N. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004:CD002140.
5. Reboul FL. Radiotherapy and chemotherapy in locally advanced nonsmall cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am 2004;18:41-53.
6. Baumann M. Accelerated radiation therapy in non-small cell lung cancer. Radiother Oncol 1999;52:97-99.
7. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137-148.
8. Belani CP, Wang W, Johnson DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2006;23:3760-3767.
9. Baggstrom MQ, Socinski MA, Hensing TA, et al. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 2002;21:306a.
10. Socinski MA, Morris DE, Masters GA, et al. American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003;123(1 suppl):226S-243S.
11. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2006;47:69-80.
12. Chen Y, Okunieff P. Radiation and third-generation chemotherapy. Hematol Oncol Clin North Am 2004;18:55-80.
13. Curran JrWJ Combined-modality therapy for inoperable non-small-cell lung cancer using gemcitabine. Clin Lung Cancer 2002;3(suppl 1):S17-S21.
14. Langer CJ. The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancer. Clin Lung Cancer 2003;4(suppl 2):S45-S49.
15. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003;13:13-21.
16. Mose S, Class R, Weber HW, et al. Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol. 2003;26:60-69.
17. Pauwels B, Korst AE, Pattyn GG, et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003;57:1075-1083.
18. Robinson BW, Ostruszka L, Im MM, et al. Promising combination therapies with gemcitabine. Semin Oncol 2004;31(2 suppl 5):2-12.
19. van Putten JW, Price A, van der Leest AH, et al. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9:2472-2477.
20. Trodella L, Granone P, Valente S, et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 2002;20:804-810.
21. McGinn CJ, Zalupski MM. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials. Int J Radiat Oncol Biol Phys 2003;56(4 suppl):10-15.
22. Joensuu TK, Kiviluoto T, Karkkainen P, et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;60:444-452.
23. Martenson JA, Vigliotti AP, Pitot HC, et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:1305-1310.
24. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-799.
25. Zarba JJ, Jaremtchuk AV, Gonzalez Jazey P, et al. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann Oncol 2003;14:1285-1290.
26. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2006;63:667-671.
27. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 2004;22:4341-4350.
28. Schild SE, Bogat JA. Innovations in the radiotherapy of non-small cell lung cancer. J Thorac Oncol 2006;1:85-92.
29. Harrison L, Shasha D, Shiaova L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28(2 suppl 8):54-59.
30. Pradier O, Lederer K, Hille A, et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol 2006;131:261-269.
31. Shi AA, Digumarthy SR, Temel JS, et al. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol 2006;1:205-210.